Nxera Joins AI Drug Discovery Consortium Backed by Microsoft, NVIDIA

Nxera Pharma joined the OpenFold AI research consortium, a non-profit group whose members include Microsoft and NVIDIA on the technology side and Bristol Myers Squibb among several pharmaceutical companies, the company said Wednesday.

The Tokyo-listed biopharma (Ticker: 4565) said the membership supports its strategy to improve R&D productivity through AI, as outlined at its March 2026 shareholder meeting. Nxera's proprietary NxWave platform combines GPCR structure-based drug discovery with computational chemistry and AI-enabled tools.

OpenFold develops open-source AI models for protein structure prediction and drug discovery, competing with proprietary systems like Google DeepMind's AlphaFold. The consortium also counts Amazon Web Services, Novo Nordisk, Bayer, and Roche among its members. Its mission is to give academic and industry researchers access to AI tools that could accelerate biological research and bring new drugs to market.

GPCRs, or G protein-coupled receptors, are membrane proteins targeted by about a third of all approved drugs. They are notoriously difficult to model with standard computational approaches. Nxera has built its platform around this specific target class, and participation in OpenFold could give its computational chemists access to shared model weights and training data that might improve prediction accuracy.

Microsoft and NVIDIA are supporting members of the consortium, providing cloud infrastructure and AI computing hardware. Neither company disclosed a separate financial contribution for Nxera's entry. Bristol Myers Squibb is one of the pharmaceutical members alongside Novo Nordisk, Bayer, and Roche. For these large companies, consortium membership represents a relatively small commitment but signals willingness to participate in open-source drug discovery development.

Microsoft, with an Alpha Score of 61/100 (moderate rating), and NVIDIA (71/100, moderate) are both covered on AlphaScala's stock pages. Bristol Myers Squibb (56/100, moderate) also carries a moderate rating. None of the three companies commented specifically on Nxera's membership.

Nxera is advancing both an internal pipeline and partnerships with larger drugmakers. The company operates from locations in Tokyo, Osaka, London, Cambridge, Basel, and Seoul. Its NxWave platform aims to move from target identification to clinical development with optimized molecules, a process the company says the OpenFold consortium could accelerate.

The consortium has not set a specific timeline for releasing new model versions. Nxera's shares trade on the Tokyo Stock Exchange and are not covered by AlphaScala's US stock pages.

For more on the participating tech and pharma companies, see the MSFT stock page, the NVDA stock page, and the BMY stock page.